Skip to main content
padlock icon - secure page this page is secure

Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen

Buy Article:

$52.00 + tax (Refund Policy)

Zhang Y, Wang Z, Robinson WR, Lim SH. Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen.

Eur J Haematol 2004: 73: 280–284. © Blackwell Munksgaard 2004. Abstract: 

We previously identified sperm protein 17 (Sp17) as a normal testicular protein aberrantly expressed in a proportion of multiple myeloma (MM). However, recent studies have generated controversies on the normal tissue expression of Sp17 and whether or not it is a suitable target for immunotherapy. In this study, we have used a combination of real time polymerase chain reaction and immunohistochemistry on a large panel of normal tissues. Although Sp17 transcripts could be detected in some normal tissues, the levels of expression were <2% of those in normal testis. In contrast, Sp17+ myeloma cells expressed 3–18% of normal testis levels of Sp17 transcript. Immunohistochemistry using two Sp17 murine monoclonal antibodies, each directed at a non-overlapping B-cell epitope, showed Sp17 protein to be expressed only in testis and not any other normal tissues. Specificity of binding of the antibodies to testis was also confirmed in competitive binding assays. Our results therefore further suggest Sp17 as a cancer-testis antigen in MM and support its suitability as a target for immunotherapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cancer-testis antigen; sperm protein 17

Document Type: Research Article

Publication date: October 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more